New Cancer Discovery
Question:
Broccoli compound inhibits breast cancer growth In the September 2004 issue of the Journal of Nutrition, researchers report that sulforaphane (SUL), a compound found in broccoli and other vegetables from the cruciferous family, has the ability to disrupt cell growth in late stage human breast cancer cells in cell culture studies. Previous research has also shown a positive benefit in reducing colon cancer growth. This is the first report to show how the naturally occurring plant chemical sulforaphane can inhibit late stages of the cancer process by disrupting components of the cell called microtubules.
– Hide quoted text — Show quoted text -> Hi All, > I thought I would share this information with you. It was printed this > past winter, 2003, in the Robert Wood Johnson Crohn’s Colitis Center of NJ > Communicator. (Somehow I never got my issue mailed and was handed one at > my last GI check up.) My GI lead the team that discovered "A Novel > Antibody for Identifying Patients at Risk for Gastric Cancer". > The full article can be found at: > http://gut.bmjjournals.com/cgi/content/full/52/6/807 > A summery of the article, published in June, 2003 issue of GUT can be > found at: > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&… > Gut. 2003 Jun;52(6):807-12. Related Articles, Links > Gastric intestinal metaplasia as detected by a monoclonal antibody is > highly associated with gastric adenocarcinoma. > Mirza ZK, Das KK, Slate J, Mapitigama RN, Amenta PS, Griffel LH, > Ramsundar L, Watari J, Yokota K, Tanabe H, Sato T, Kohgo Y, Das KM. > Department of Medicine and Pathology, UMDNJ-Robert Wood Johnson Medical > School, New Brunswick, NJ 08903, USA. > BACKGROUND: Some forms of gastric intestinal metaplasia (GIM) may be > precancerous but the cellular phenotype that predisposes to gastric > carcinogenesis is not well characterised. Mucin staining, as a means of > differentiating GIM, is difficult. A monoclonal antibody, mAb Das-1 > (initially called 7E(12)H(12)), whose staining is phenotypically specific > to colon epithelium, was used to investigate this issue. METHODS: Using > mAb Das-1, by a sensitive immunoperoxidase assay, we examined > histologically confirmed GIM specimens from two countries, the USA and > Japan. A total of 150 patients comprised three groups: group A, GIM > (fields away from the cancer area) from patients with gastric carcinoma > (n=60); group B, GIM with chronic gastritis (without gastric carcinoma) > (n=72); and group C, chronic gastritis without GIM (n=18). RESULTS: Fifty > six of 60 (93%) patients with GIM (both goblet and non-goblet metaplastic > cells) from group A reacted intensely with mAb Das-1. Cancer areas fr > om the same 56 patients also reacted. In contrast, 25/72 (35%) samples of > GIM from patients in group B reacted with mAb Das-1 (group A v B, > p<0.0001). None of the samples from group C reacted with the mAb. > CONCLUSIONS: Reactivity of mAb Das-1 is clinically useful to simplify and > differentiate the phenotypes of GIM. The colonic phenotype of GIM, as > identified by mAb Das-1, is strongly associated with gastric carcinoma. > PMID: 12740335 [PubMed - indexed for MEDLINE] > Who knows, maybe someday soon this can lead to non-invasive a screening > test for this and other cancers. Would no more colonoscopies be too much > to ask for? > 
mgbio
Response:
>I was getting quality health care before I needed colonoscopy. I would >welcome a screening option that did not include my ingesting something that >forced my system to expel all of the stool from my system; then undergo >sedation and pain relief so an instrument could be inserted into my rectum, >through my colon and into my small bowel. If a non-invasive method of >cancer detection could be developed that was just as or more effective than >colonoscopy I would welcome it with open arms. Why wouldn’t you? > mgbio
Because I just don’t feel loved if I don’t go through extensive periods of torture, ingesting disgusting and quickly expelled substances that – at this point – all smell like gatorade anyway, to culminate in prison-like love. (The previous post was sarcasm, btw. )
Response:
I was getting quality health care before I needed colonoscopy. I would welcome a screening option that did not include my ingesting something that forced my system to expel all of the stool from my system; then undergo sedation and pain relief so an instrument could be inserted into my rectum, through my colon and into my small bowel. If a non-invasive method of cancer detection could be developed that was just as or more effective than colonoscopy I would welcome it with open arms. Why wouldn’t you? mgbio – Hide quoted text — Show quoted text ->Hi All, >Who knows, maybe someday soon this can lead to non-invasive a screening >test for this and other cancers. Would no more colonoscopies be too much >to ask for? > How would you know you were getting quality health-care if not for the > occasional rectal invasion? Sure makes *me* feel … healthy.
Response:
> Hi All, > Who knows, maybe someday soon this can lead to non-invasive a screening > test for this and other cancers. Would no more colonoscopies be too much > to ask for?
How would you know you were getting quality health-care if not for the occasional rectal invasion? Sure makes *me* feel … healthy.
Response:
Hi All, I thought I would share this information with you. It was printed this past winter, 2003, in the Robert Wood Johnson Crohn’s Colitis Center of NJ Communicator. (Somehow I never got my issue mailed and was handed one at my last GI check up.) My GI lead the team that discovered "A Novel Antibody for Identifying Patients at Risk for Gastric Cancer". The full article can be found at: http://gut.bmjjournals.com/cgi/content/full/52/6/807 A summery of the article, published in June, 2003 issue of GUT can be found at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&… Gut. 2003 Jun;52(6):807-12. Related Articles, Links Gastric intestinal metaplasia as detected by a monoclonal antibody is highly associated with gastric adenocarcinoma. Mirza ZK, Das KK, Slate J, Mapitigama RN, Amenta PS, Griffel LH, Ramsundar L, Watari J, Yokota K, Tanabe H, Sato T, Kohgo Y, Das KM. Department of Medicine and Pathology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA. BACKGROUND: Some forms of gastric intestinal metaplasia (GIM) may be precancerous but the cellular phenotype that predisposes to gastric carcinogenesis is not well characterised. Mucin staining, as a means of differentiating GIM, is difficult. A monoclonal antibody, mAb Das-1 (initially called 7E(12)H(12)), whose staining is phenotypically specific to colon epithelium, was used to investigate this issue. METHODS: Using mAb Das-1, by a sensitive immunoperoxidase assay, we examined histologically confirmed GIM specimens from two countries, the USA and Japan. A total of 150 patients comprised three groups: group A, GIM (fields away from the cancer area) from patients with gastric carcinoma (n=60); group B, GIM with chronic gastritis (without gastric carcinoma) (n=72); and group C, chronic gastritis without GIM (n=18). RESULTS: Fifty six of 60 (93%) patients with GIM (both goblet and non-goblet metaplastic cells) from group A reacted intensely with mAb Das-1. Cancer areas fr om the same 56 patients also reacted. In contrast, 25/72 (35%) samples of GIM from patients in group B reacted with mAb Das-1 (group A v B, p<0.0001). None of the samples from group C reacted with the mAb. CONCLUSIONS: Reactivity of mAb Das-1 is clinically useful to simplify and differentiate the phenotypes of GIM. The colonic phenotype of GIM, as identified by mAb Das-1, is strongly associated with gastric carcinoma. PMID: 12740335 [PubMed - indexed for MEDLINE] Who knows, maybe someday soon this can lead to non-invasive a screening test for this and other cancers. Would no more colonoscopies be too much to ask for? mgbio
Response:
Related Posts